Centre Hospitalier St Joseph St Luc
Lyon, 69007, France
NCT Number: NCT04422977
A seroconversion test for SARS-Cov-2 will be offered to all the employees of a care institution, which has treated 240 patients hospitalized for COVID disease between 28/02 and 30/04/2020. The seroconversion test will be with a questionnaire to determine:
* whether the subject has shown signs of infection in the last 3 recent months * if the subject has been in contact with COVID-diagnosed subjects (RT-PCR diagnosis or scanner) outside of the activity or within the professional activity (patient or colleague) * Working conditions during the period * The level of knowledge and respect of the barrier measures practices. * Respect for distance during meals professional. Overall seroprevalence and stratified seroprevalence by care and administrative areas will be determined.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
Lyon, 69007, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff
Other names: serology
Time frame: 1 month
Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff
Centre Hospitalier Saint Joseph Saint Luc de Lyon
Other
Serological Study of the Exposure of Personnel to Sars-cov-2 in an Urban Hospital Two Months After Managing an Influx of COVID Patients 19
Acronym: SEROPHUGAC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04353609
Autoimmune Diseases, COVID-19
Lille, France
View Trial DetailsNCT04356495
Corona Virus Infection, Coronaviridae Infections
Bordeaux, France
View Trial DetailsNCT04378842
COVID-19, Coronaviridae Infections
Amiens, France
View Trial DetailsNCT04393974
Cancer, Neoplasms
Brussels, Belgium
View Trial Details